Indaptus Therapeutics (NASDAQ:INDP) Releases Earnings Results, Beats Expectations By $0.07 EPS

Indaptus Therapeutics (NASDAQ:INDP) issued its quarterly earnings results on Monday. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.07, Zacks reports.

Indaptus Therapeutics Stock Up 0.6 %

INDP traded up $0.01 during trading on Wednesday, hitting $1.68. 2,931 shares of the stock were exchanged, compared to its average volume of 45,080. The firm has a market capitalization of $14.35 million, a P/E ratio of -0.94 and a beta of 1.39. Indaptus Therapeutics has a 1-year low of $1.56 and a 1-year high of $4.08. The stock has a fifty day moving average price of $2.17 and a two-hundred day moving average price of $2.16.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Indaptus Therapeutics in a report on Monday, June 17th.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.